{
  "guideline": {
    "id": "PA166104892",
    "name": "Annotation of FDA Label for sulfasalazine and G6PD, NAT2",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 33,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104892",
    "relatedChemicals": [
      {
        "id": "PA451547",
        "name": "sulfasalazine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA28469",
        "name": "glucose-6-phosphate dehydrogenase",
        "symbol": "G6PD"
      },
      {
        "id": "PA18",
        "name": "N-acetyltransferase 2",
        "symbol": "NAT2"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312421",
      "name": "Recommendation Annotation PA166312421",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451547",
          "name": "sulfasalazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216720,
        "html": "<p>&quot;Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312386",
      "name": "Recommendation Annotation PA166312386",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451547",
          "name": "sulfasalazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216666,
        "html": "<p>&quot;Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient with CNSHA"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315121",
      "name": "Recommendation Annotation PA166315121",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451547",
          "name": "sulfasalazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452245660,
        "html": "<p>&quot;Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Variable"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Sulfasalazine (Sulfasalazine), NDA007073, REMEDYREPACK INC.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=007073"
    }
  ],
  "version": "2024-03-08-14-34"
}